Related Experiment Video
Updated: May 21, 2026
Generation of Human 3D Lung Tissue Cultures (3D-LTCs) for Disease Modeling
Published on: February 12, 2019
Breathing life into fibrosis research: precision-cut lung slices, organoids, and organs-on-chip as transformative
Bingying Lu1, Zhe Lv1, Xinyu Zhang1
1Department of Immunology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, People's Republic of China.
Abstract:
Pulmonary fibrosis represents one of the most challenging frontiers in respiratory medicine, characterized by progressive scarring that ultimately leads to respiratory failure and death. Despite decades of research, therapeutic options remain frustratingly limited, with only three Food and Drug Administration-approved agents that merely slow disease progression without reversing established fibrosis. This therapeutic impasse stems largely from the translational disconnect between traditional preclinical models and human disease complexity. Animal models fail to recapitulate the chronic, progressive nature of human fibrosis, while conventional cell culture systems cannot capture the intricate three-dimensional architecture and multicellular interactions that drive fibrotic remodeling. The emergence of new approach methodologies has catalyzed a paradigm shift in pulmonary fibrosis research, offering unprecedented opportunities to model human disease with greater fidelity. This review examines three revolutionary platforms that are reshaping our understanding of fibrotic mechanisms: precision-cut lung slices that preserve native tissue architecture, self-organizing lung organoids that enable patient-specific disease modeling, and microfluidic lung-on-chip systems that recreate physiological breathing mechanics. We critically evaluate the unique capabilities and inherent limitations of each technology, explore their applications in mechanistic studies and drug discovery, and discuss emerging hybrid approaches that promise to accelerate therapeutic development. By synthesizing current evidence and identifying future directions, this review provides a roadmap for leveraging these innovative technologies to finally break through the therapeutic ceiling in pulmonary fibrosis.
Insights
New lung models like precision-cut slices, organoids, and lung-on-chip systems offer better ways to study pulmonary fibrosis. These advanced methods promise to accelerate the development of effective treatments for this challenging respiratory disease.
Area of Science:
- Pulmonary medicine and regenerative biology.
Background:
- Pulmonary fibrosis is a progressive lung scarring disease with limited treatment options.
- Current preclinical models fail to accurately replicate human fibrotic disease complexity.
- There is a critical need for advanced models to understand disease mechanisms and develop therapies.
Purpose of the Study:
- To review novel New Approach Methodologies (NAMs) for modeling pulmonary fibrosis.
- To evaluate precision-cut lung slices, lung organoids, and lung-on-chip systems.
- To discuss their potential in advancing mechanistic studies and drug discovery for pulmonary fibrosis.
Main Methods:
- Review of literature on three key NAMs: precision-cut lung slices, lung organoids, and microfluidic lung-on-chip systems.
- Critical evaluation of the capabilities and limitations of each technology.
- Exploration of applications in disease modeling and therapeutic development.
Main Results:
- Precision-cut lung slices preserve native lung architecture for studying fibrosis.
- Lung organoids allow for patient-specific modeling of fibrotic diseases.
- Lung-on-chip systems mimic physiological breathing mechanics to model fibrosis.
Conclusions:
- These NAMs represent a paradigm shift in pulmonary fibrosis research.
- They offer greater fidelity in modeling human fibrotic lung disease compared to traditional models.
- These innovative platforms hold significant promise for accelerating the development of novel therapeutics.
